Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 701

Results For "RAT"

7021 News Found

Lupin receives approval for tavaborole topical solution
News | February 10, 2021

Lupin receives approval for tavaborole topical solution

Tavaborole Topical Solution, 5%, is an oxaborole antifungal.


WACKER acquires plasmid DNA Manufacturer Genopis
News | February 05, 2021

WACKER acquires plasmid DNA Manufacturer Genopis

WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).


Biocon Biologics to offer its oncology biosimilars in 30+ countries
Biotech | February 05, 2021

Biocon Biologics to offer its oncology biosimilars in 30+ countries

The partnership is a significant step in delivering advanced cancer therapies to patients.


DKSH to distribute analytical instruments of NanoFCM in Asia
News | February 02, 2021

DKSH to distribute analytical instruments of NanoFCM in Asia

This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market


Laurus Q3 FY21 revenue up 76%; PAT grows 274%
News | January 29, 2021

Laurus Q3 FY21 revenue up 76%; PAT grows 274%

The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.


Lonza reports 12% sales growth in 2020
News | January 28, 2021

Lonza reports 12% sales growth in 2020

Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.


Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities
News | January 26, 2021

Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities

Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.


Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr
News | January 23, 2021

Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr

EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.


Syngene Q3 revenue up 13% to Rs. 585 Cr
News | January 22, 2021

Syngene Q3 revenue up 13% to Rs. 585 Cr

EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.